Now showing items 1-20 of 133

    • 18F-FDG PET/CT Optimizes Treatment in Staphylococcus Aureus Bacteremia and Is Associated with Reduced Mortality. 

      Berrevoets, MAH; Kouijzer, IJE; Aarntzen, EHJG; Janssen, MJR; De Geus-Oei, L-F; Wertheim, HFL; Kullberg, B-J; Oever, JT; Oyen, WJG; Bleeker-Rovers, CP (2017-09)
      Metastatic infection is an important complication of Staphylococcus aureus bacteremia (SAB). Early diagnosis of metastatic infection is crucial, because specific treatment is required. However, metastatic infection can be ...
    • Accuracy of screening women at familial risk of breast cancer without a known gene mutation: Individual patient data meta-analysis. 

      Phi, X-A; Houssami, N; Hooning, MJ; Riedl, CC; Leach, MO; Sardanelli, F; Warner, E; Trop, I; Saadatmand, S; Tilanus-Linthorst, MMA; Helbich, TH; van den Heuvel, ER; de Koning, HJ; Obdeijn, I-M; de Bock, GH (2017-11)
      Women with a strong family history of breast cancer (BC) and without a known gene mutation have an increased risk of developing BC. We aimed to investigate the accuracy of screening using annual mammography with or without ...
    • Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis. 

      Ghidini, M; Tomasello, G; Botticelli, A; Barni, S; Zabbialini, G; Seghezzi, S; Passalacqua, R; Braconi, C; Petrelli, F (2017-09)
      The use of adjuvant treatment (AT) in resected biliary tract cancers (BTC) is still controversial. No efficacy comparison has been performed between chemotherapy (CT) and chemoradiotherapy (CTRT). A systematic review of ...
    • Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk. 

      Sud, A; Chattopadhyay, S; Thomsen, H; Sundquist, K; Sundquist, J; Houlston, RS; Hemminki, K (2019-09)
      Estimating familial cancer risks is clinically important in being able to discriminate between individuals in the population at differing risk for malignancy. To gain insight into the familial risk for the different ...
    • Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. 

      Conteduca, V; Wetterskog, D; Sharabiani, MTA; Grande, E; Fernandez-Perez, MP; Jayaram, A; Salvi, S; Castellano, D; Romanel, A; Romanel, A; Lolli, C; Casadio, V; Gurioli, G; Amadori, D; Font, A; Vazquez-Estevez, S; González Del Alba, A; Mellado, B; Fernandez-Calvo, O; Méndez-Vidal, MJ; Climent, MA; Duran, I; Gallardo, E; Rodriguez, A; Santander, C; Sáez, MI; Puente, J; Gasi Tandefelt, D; Wingate, A; Dearnaley, D; PREMIERE Collaborators; Spanish Oncology Genitourinary Group; Demichelis, F; De Giorgi, U; Gonzalez-Billalabeitia, E; Attard, G (2017-07)
      Background:There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma ...
    • Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. 

      Barton, S; Zabaglo, L; A'Hern, R; Turner, N; Ferguson, T; O'Neill, S; Hills, M; Smith, I; Dowsett, M (2012-05)
      BACKGROUND:The immunohistochemical (IHC) 4+C score is a cost-effective prognostic tool that uses clinicopathologic factors and four standard IHC assays: oestrogen receptor (ER), PR, HER2 and Ki67. We assessed its utility ...
    • Association analyses identify 31 new risk loci for colorectal cancer susceptibility. 

      Law, PJ; Timofeeva, M; Fernandez-Rozadilla, C; Broderick, P; Studd, J; Fernandez-Tajes, J; Farrington, S; Svinti, V; Palles, C; Orlando, G; Sud, A; Holroyd, A; Penegar, S; Theodoratou, E; Vaughan-Shaw, P; Campbell, H; Zgaga, L; Hayward, C; Campbell, A; Harris, S; Deary, IJ; Starr, J; Gatcombe, L; Pinna, M; Briggs, S; Martin, L; Jaeger, E; Sharma-Oates, A; East, J; Leedham, S; Arnold, R; Johnstone, E; Wang, H; Kerr, D; Kerr, R; Maughan, T; Kaplan, R; Al-Tassan, N; Palin, K; Hänninen, UA; Cajuso, T; Tanskanen, T; Kondelin, J; Kaasinen, E; Sarin, A-P; Eriksson, JG; Rissanen, H; Knekt, P; Pukkala, E; Jousilahti, P; Salomaa, V; Ripatti, S; Palotie, A; Renkonen-Sinisalo, L; Lepistö, A; Böhm, J; Mecklin, J-P; Buchanan, DD; Win, A-K; Hopper, J; Jenkins, ME; Lindor, NM; Newcomb, PA; Gallinger, S; Duggan, D; Casey, G; Hoffmann, P; Nöthen, MM; Jöckel, K-H; Easton, DF; Pharoah, PDP; Peto, J; Canzian, F; Swerdlow, A; Eeles, RA; Kote-Jarai, Z; Muir, K; Pashayan, N; PRACTICAL consortium; Harkin, A; Allan, K; McQueen, J; Paul, J; Iveson, T; Saunders, M; Butterbach, K; Chang-Claude, J; Hoffmeister, M; Brenner, H; Kirac, I; Matošević, P; Hofer, P; Brezina, S; Gsur, A; Cheadle, JP; Aaltonen, LA; Tomlinson, I; Houlston, RS; Dunlop, MG (2019-05-14)
      Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, and has a strong heritable basis. We report a genome-wide association analysis of 34,627 CRC cases and 71,379 controls of European ancestry that ...
    • Association between Adult Height and Risk of Colorectal, Lung, and Prostate Cancer: Results from Meta-analyses of Prospective Studies and Mendelian Randomization Analyses. 

      Khankari, NK; Shu, X-O; Wen, W; Kraft, P; Lindström, S; Peters, U; Schildkraut, J; Schumacher, F; Bofetta, P; Risch, A; Bickeböller, H; Amos, CI; Easton, D; Eeles, RA; Eeles, RA; Gruber, SB; Haiman, CA; Hunter, DJ; Chanock, SJ; Pierce, BL; Zheng, W; Colorectal Transdisciplinary Study (CORECT); Discovery, Biology, and Risk of Inherited Variants in Breast Cancer (DRIVE); Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE); Transdisciplinary Research in Cancer of the Lung (TRICL) (2016-09-06)
      BACKGROUND:Observational studies examining associations between adult height and risk of colorectal, prostate, and lung cancers have generated mixed results. We conducted meta-analyses using data from prospective cohort ...
    • Association of Body Mass Index and Age With Subsequent Breast Cancer Risk in Premenopausal Women. 

      Premenopausal Breast Cancer Collaborative Group; Schoemaker, MJ; Nichols, HB; Wright, LB; Brook, MN; Jones, ME; O'Brien, KM; Adami, H-O; Baglietto, L; Bernstein, L; Bertrand, KA; Boutron-Ruault, M-C; Braaten, T; Chen, Y; Connor, AE; Dorronsoro, M; Dossus, L; Eliassen, AH; Giles, GG; Hankinson, SE; Kaaks, R; Key, TJ; Kirsh, VA; Kitahara, CM; Koh, W-P; Larsson, SC; Linet, MS; Ma, H; Masala, G; Merritt, MA; Milne, RL; Overvad, K; Ozasa, K; Palmer, JR; Peeters, PH; Riboli, E; Rohan, TE; Sadakane, A; Sund, M; Tamimi, RM; Trichopoulou, A; Ursin, G; Vatten, L; Visvanathan, K; Weiderpass, E; Willett, WC; Wolk, A; Yuan, J-M; Zeleniuch-Jacquotte, A; Sandler, DP; Swerdlow, AJ (2018-11-08)
      Importance:The association between increasing body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) and risk of breast cancer is unique in cancer epidemiology in that a crossover ...
    • Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. 

      Hamdi, Y; Soucy, P; Adoue, V; Michailidou, K; Canisius, S; Lemaçon, A; Droit, A; Andrulis, IL; Anton-Culver, H; Arndt, V; Baynes, C; Blomqvist, C; Bogdanova, NV; Bojesen, SE; Bolla, MK; Bonanni, B; Borresen-Dale, A-L; Brand, JS; Brauch, H; Brenner, H; Broeks, A; Burwinkel, B; Chang-Claude, J; NBCS Collaborators; Couch, FJ; Cox, A; Cross, SS; Czene, K; Darabi, H; Dennis, J; Devilee, P; Dörk, T; Dos-Santos-Silva, I; Eriksson, M; Fasching, PA; Figueroa, J; Flyger, H; García-Closas, M; Giles, GG; Goldberg, MS; González-Neira, A; Grenaker-Alnæs, G; Guénel, P; Haeberle, L; Haiman, CA; Hamann, U; Hallberg, E; Hooning, MJ; Hopper, JL; Jakubowska, A; Jones, M; Kabisch, M; Kataja, V; Lambrechts, D; Le Marchand, L; Lindblom, A; Lubinski, J; Mannermaa, A; Maranian, M; Margolin, S; Marme, F; Milne, RL; Neuhausen, SL; Nevanlinna, H; Neven, P; Olswold, C; Peto, J; Plaseska-Karanfilska, D; Pylkäs, K; Radice, P; Rudolph, A; Sawyer, EJ; Schmidt, MK; Shu, X-O; Southey, MC; Swerdlow, A; Tollenaar, RAEM; Tomlinson, I; Torres, D; Truong, T; Vachon, C; Van Den Ouweland, AMW; Wang, Q; Winqvist, R; kConFab/AOCS Investigators; Zheng, W; Benitez, J; Chenevix-Trench, G; Dunning, AM; Pharoah, PDP; Kristensen, V; Hall, P; Easton, DF; Pastinen, T; Nord, S; Simard, J (2016-12)
      There are significant inter-individual differences in the levels of gene expression. Through modulation of gene expression, cis-acting variants represent an important source of phenotypic variation. Consequently, cis-regulatory ...
    • Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. 

      Zhao, Z; Wen, W; Michailidou, K; Bolla, MK; Wang, Q; Zhang, B; Long, J; Shu, X-O; Schmidt, MK; Milne, RL; García-Closas, M; Chang-Claude, J; Lindstrom, S; Bojesen, SE; Ahsan, H; Aittomäki, K; Andrulis, IL; Anton-Culver, H; Arndt, V; Beckmann, MW; Beeghly-Fadiel, A; Benitez, J; Blomqvist, C; Bogdanova, NV; Børresen-Dale, A-L; Brand, J; Brauch, H; Brenner, H; Burwinkel, B; Cai, Q; Casey, G; Chenevix-Trench, G; Couch, FJ; Cox, A; Cross, SS; Czene, K; Dörk, T; Dumont, M; Fasching, PA; Figueroa, J; Flesch-Janys, D; Fletcher, O; Flyger, H; Fostira, F; Gammon, M; Giles, GG; Guénel, P; Haiman, CA; Hamann, U; Harrington, P; Hartman, M; Hooning, MJ; Hopper, JL; Jakubowska, A; Jasmine, F; John, EM; Johnson, N; Kabisch, M; Khan, S; Kibriya, M; Knight, JA; Kosma, V-M; Kriege, M; Kristensen, V; Le Marchand, L; Lee, E; Li, J; Lindblom, A; Lophatananon, A; Luben, R; Lubinski, J; Malone, KE; Mannermaa, A; Manoukian, S; Margolin, S; Marme, F; McLean, C; Meijers-Heijboer, H; Meindl, A; Miao, H; Muir, K; Neuhausen, SL; Nevanlinna, H; Neven, P; Olson, JE; Perkins, B; Peterlongo, P; Phillips, K-A; Pylkäs, K; Rudolph, A; Santella, R; Sawyer, EJ; Schmutzler, RK; Schoemaker, M; Shah, M; Shrubsole, M; Southey, MC; Swerdlow, AJ; Toland, AE; Tomlinson, I; Torres, D; Truong, T; Ursin, G; Van Der Luijt, RB; Verhoef, S; Wang-Gohrke, S; Whittemore, AS; Winqvist, R; Pilar Zamora, M; Zhao, H; Dunning, AM; Simard, J; Hall, P; Kraft, P; Pharoah, P; Hunter, D; Easton, DF; Zheng, W (2016-05)
      Type 2 diabetes (T2D) has been reported to be associated with an elevated risk of breast cancer. It is unclear, however, whether this association is due to shared genetic factors.We constructed a genetic risk score (GRS) ...
    • BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). 

      Kelly, JD; Tan, WS; Porta, N; Mostafid, H; Huddart, R; Protheroe, A; Bogle, R; Blazeby, J; Palmer, A; Cresswell, J; Johnson, M; Brough, R; Madaan, S; Andrews, S; Cruickshank, C; Burnett, S; Maynard, L; Hall, E; BOXIT Investigators (2019-04)
      BACKGROUND:Non-muscle-invasive bladder cancer (NMIBC) has a significant risk of recurrence despite adjuvant intravesical therapy. OBJECTIVE:To determine whether celecoxib, a cyclo-oxygenase 2 inhibitor, reduces the risk ...
    • BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). 

      Kelly, JD; Tan, WS; Porta, N; Mostafid, H; Huddart, R; Protheroe, A; Bogle, R; Blazeby, J; Palmer, A; Cresswell, J; Johnson, M; Brough, R; Madaan, S; Andrews, S; Cruickshank, C; Burnett, S; Maynard, L; Hall, E; BOXIT Investigators (2019-04)
      BACKGROUND:Non-muscle-invasive bladder cancer (NMIBC) has a significant risk of recurrence despite adjuvant intravesical therapy. OBJECTIVE:To determine whether celecoxib, a cyclo-oxygenase 2 inhibitor, reduces the risk ...
    • Breast Cancer Risk After Recent Childbirth: A Pooled Analysis of 15 Prospective Studies. 

      Nichols, HB; Schoemaker, MJ; Cai, J; Xu, J; Wright, LB; Brook, MN; Jones, ME; Adami, H-O; Baglietto, L; Bertrand, KA; Blot, WJ; Boutron-Ruault, M-C; Dorronsoro, M; Dossus, L; Eliassen, AH; Giles, GG; Gram, IT; Hankinson, SE; Hoffman-Bolton, J; Kaaks, R; Key, TJ; Kitahara, CM; Larsson, SC; Linet, M; Merritt, MA; Milne, RL; Pala, V; Palmer, JR; Peeters, PH; Riboli, E; Sund, M; Tamimi, RM; Tjønneland, A; Trichopoulou, A; Ursin, G; Vatten, L; Visvanathan, K; Weiderpass, E; Wolk, A; Zheng, W; Weinberg, CR; Swerdlow, AJ; Sandler, DP (2019-01)
      Background:Parity is widely recognized as protective for breast cancer, but breast cancer risk may be increased shortly after childbirth. Whether this risk varies with breastfeeding, family history of breast cancer, or ...
    • Breast cancer risk in relation to history of preeclampsia and hyperemesis gravidarum: Prospective analysis in the Generations Study. 

      Wright, LB; Schoemaker, MJ; Jones, ME; Ashworth, A; Swerdlow, AJ (2018-08)
      Preeclampsia and hyperemesis gravidarum are pregnancy complications associated with altered sex hormone levels. Previous studies suggest preeclampsia may be associated with a decreased risk of subsequent breast cancer and ...
    • Breast cancer risk prediction in women aged 35-50 years: impact of including sex hormone concentrations in the Gail model. 

      Clendenen, TV; Ge, W; Koenig, KL; Afanasyeva, Y; Agnoli, C; Brinton, LA; Darvishian, F; Dorgan, JF; Eliassen, AH; Falk, RT; Hallmans, G; Hankinson, SE; Hoffman-Bolton, J; Key, TJ; Krogh, V; Nichols, HB; Sandler, DP; Schoemaker, MJ; Sluss, PM; Sund, M; Swerdlow, AJ; Visvanathan, K; Zeleniuch-Jacquotte, A; Liu, M (2019-03-19)
      BACKGROUND:Models that accurately predict risk of breast cancer are needed to help younger women make decisions about when to begin screening. Premenopausal concentrations of circulating anti-Müllerian hormone (AMH), a ...
    • Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. 

      Dunning, AM; Michailidou, K; Kuchenbaecker, KB; Thompson, D; French, JD; Beesley, J; Healey, CS; Kar, S; Pooley, KA; Lopez-Knowles, E; Dicks, E; Barrowdale, D; Sinnott-Armstrong, NA; Sallari, RC; Hillman, KM; Kaufmann, S; Sivakumaran, H; Moradi Marjaneh, M; Lee, JS; Hills, M; Jarosz, M; Drury, S; Canisius, S; Bolla, MK; Dennis, J; Wang, Q; Hopper, JL; Southey, MC; Broeks, A; Schmidt, MK; Lophatananon, A; Muir, K; Beckmann, MW; Fasching, PA; Dos-Santos-Silva, I; Peto, J; Sawyer, EJ; Tomlinson, I; Burwinkel, B; Marme, F; Guénel, P; Truong, T; Bojesen, SE; Flyger, H; González-Neira, A; Perez, JIA; Anton-Culver, H; Eunjung, L; Arndt, V; Brenner, H; Meindl, A; Schmutzler, RK; Brauch, H; Hamann, U; Aittomäki, K; Blomqvist, C; Ito, H; Matsuo, K; Bogdanova, N; Dörk, T; Lindblom, A; Margolin, S; Kosma, V-M; Mannermaa, A; Tseng, C-C; Wu, AH; Lambrechts, D; Wildiers, H; Chang-Claude, J; Rudolph, A; Peterlongo, P; Radice, P; Olson, JE; Giles, GG; Milne, RL; Haiman, CA; Henderson, BE; Goldberg, MS; Teo, SH; Yip, CH; Nord, S; Borresen-Dale, A-L; Kristensen, V; Long, J; Zheng, W; Pylkäs, K; Winqvist, R; Andrulis, IL; Knight, JA; Devilee, P; Seynaeve, C; Figueroa, J; Sherman, ME; Czene, K; Darabi, H; Hollestelle, A; van den Ouweland, AMW; Humphreys, K; Gao, Y-T; Shu, X-O; Cox, A; Cross, SS; Blot, W; Cai, Q; Ghoussaini, M; Perkins, BJ; Shah, M; Choi, J-Y; Kang, D; Lee, SC; Hartman, M; Kabisch, M; Torres, D; Jakubowska, A; Lubinski, J; Brennan, P; Sangrajrang, S; Ambrosone, CB; Toland, AE; Shen, C-Y; Wu, P-E; Orr, N; Swerdlow, A; McGuffog, L; Healey, S; Lee, A; Kapuscinski, M; John, EM; Terry, MB; Daly, MB; Goldgar, DE; Buys, SS; Janavicius, R; Tihomirova, L; Tung, N; Dorfling, CM; van Rensburg, EJ; Neuhausen, SL; Ejlertsen, B; Hansen, TVO; Osorio, A; Benitez, J; Rando, R; Weitzel, JN; Bonanni, B; Peissel, B; Manoukian, S; Papi, L; Ottini, L; Konstantopoulou, I; Apostolou, P; Garber, J; Rashid, MU; Frost, D; EMBRACE; Izatt, L; Ellis, S; Godwin, AK; Arnold, N; Niederacher, D; Rhiem, K; Bogdanova-Markov, N; Sagne, C; Stoppa-Lyonnet, D; Damiola, F; GEMO Study Collaborators; Sinilnikova, OM; Mazoyer, S; Isaacs, C; Claes, KBM; De Leeneer, K; de la Hoya, M; Caldes, T; Nevanlinna, H; Khan, S; Mensenkamp, AR; HEBON; Hooning, MJ; Rookus, MA; Kwong, A; Olah, E; Diez, O; Brunet, J; Pujana, MA; Gronwald, J; Huzarski, T; Barkardottir, RB; Laframboise, R; Soucy, P; Montagna, M; Agata, S; Teixeira, MR; kConFab Investigators; Park, SK; Lindor, N; Couch, FJ; Tischkowitz, M; Foretova, L; Vijai, J; Offit, K; Singer, CF; Rappaport, C; Phelan, CM; Greene, MH; Mai, PL; Rennert, G; Imyanitov, EN; Hulick, PJ; Phillips, K-A; Piedmonte, M; Mulligan, AM; Glendon, G; Bojesen, A; Thomassen, M; Caligo, MA; Yoon, S-Y; Friedman, E; Laitman, Y; Borg, A; von Wachenfeldt, A; Ehrencrona, H; Rantala, J; Olopade, OI; Ganz, PA; Nussbaum, RL; Gayther, SA; Nathanson, KL; Domchek, SM; Arun, BK; Mitchell, G; Karlan, BY; Lester, J; Maskarinec, G; Woolcott, C; Scott, C; Stone, J; Apicella, C; Tamimi, R; Luben, R; Khaw, K-T; Helland, Å; Haakensen, V; Dowsett, M; Pharoah, PDP; Simard, J; Hall, P; García-Closas, M; Vachon, C; Chenevix-Trench, G; Antoniou, AC; Easton, DF; Edwards, SL (2016-04)
      We analyzed 3,872 common genetic variants across the ESR1 locus (encoding estrogen receptor α) in 118,816 subjects from three international consortia. We found evidence for at least five independent causal variants, each ...
    • Can routine data be used to support cancer clinical trials? A historical baseline on which to build: retrospective linkage of data from the TACT (CRUK 01/001) breast cancer trial and the National Cancer Data Repository. 

      Kilburn, LS; Aresu, M; Banerji, J; Barrett-Lee, P; Ellis, P; Bliss, JM (2017-11-23)
      Randomised clinical trials (RCTs) are the gold standard for evaluating new cancer treatments. They are, however, expensive to conduct, particularly where long-term follow-up of participants is required. Tracking participants ...
    • Candidate gene association studies and risk of Hodgkin lymphoma: a systematic review and meta-analysis. 

      Sud, A; Hemminki, K; Houlston, RS (2017-03)
      To evaluate the contribution of association studies of candidate polymorphisms to inherited predisposition to Hodgkin lymphoma (HL), we conducted a systematic review and meta-analysis of published case-control studies. Of ...
    • Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts. 

      Ge, W; Clendenen, TV; Afanasyeva, Y; Koenig, KL; Agnoli, C; Brinton, LA; Dorgan, JF; Eliassen, AH; Falk, RT; Hallmans, G; Hankinson, SE; Hoffman-Bolton, J; Key, TJ; Krogh, V; Nichols, HB; Sandler, DP; Schoemaker, MJ; Sluss, PM; Sund, M; Swerdlow, AJ; Visvanathan, K; Liu, M; Zeleniuch-Jacquotte, A (2018-06)
      A strong positive association has been observed between circulating anti-Müllerian hormone (AMH), a biomarker of ovarian reserve, and breast cancer risk in three prospective studies. Confirming this association is important ...